Independent directory Public ClinicalTrials.gov records United States
Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 2,626 matching trials from the local directory fallback.
Conditions
Prostate Adenocarcinoma
Interventions
Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
567
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
594
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more
Conditions
PMM2-CDG, Phosphomannomutase 2 Deficiency
Interventions
GLM101 (Part A, Double-blind), GLM101 (Part B, Open-label), Placebo (Part A, Double-blind)
Drug
Lead sponsor
Glycomine, Inc.
Industry
Eligibility
4 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Minneapolis, Minnesota • New York, New York • Philadelphia, Pennsylvania + 1 more
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
ATP150, ATP152, ATP162, Ezabenlimab, VSV-GP154
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 9 more
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Daratumumab, Dexamethasone, Etentamig, Lenalidomide, Pomalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
15
States / cities
Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more
Conditions
Advanced Solid Neoplasms
Interventions
Olaparib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
24
States / cities
Tucson, Arizona • Fullerton, California • Los Angeles, California + 17 more
Conditions
Posttraumatic Stress Disorder
Interventions
Placebo, Prazosin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Crohn's Disease
Interventions
Placebo for Risankizumab IV, Placebo for Risankizumab SC, Risankizumab IV, Risankizumab On-Body Injector (OBI), Risankizumab SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
111
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
Conditions
Alcohol Use Disorder (AUD), PTSD
Interventions
Maltodextrin (Placebo), Psilocybin 25 mg
Drug
Lead sponsor
Nathan Brashares Sackett
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Myeloproliferative Neoplasm, Primary Myelofibrosis
Interventions
Placebo, Ropeginterferon alfa-2b
Other · Biological
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Kansas City, Kansas + 10 more
Active, not recruiting Not applicable Interventional

Desara ® One Single Incision Sling 522 Study

NCT04772131
Conditions
Stress Urinary Incontinence
Interventions
Desara® Blue Transobturator Sling, Desara® One Single Incision Sling
Device
Lead sponsor
Caldera Medical, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Tucson, Arizona • Hialeah, Florida + 12 more
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
54
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of CHS-114 in Participants With Advanced Solid Tumors

NCT05635643
Conditions
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Interventions
CHS-114, toripalimab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
12
States / cities
Palo Alto, California • Atlanta, Georgia • Louisville, Kentucky + 9 more
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
Conditions
Acute Liver Failure, Acute Liver Injury, Fulminant Hepatic Failure, Hepatic Encephalopathy, Immune Dysregulation
Interventions
Diphenhydramine, Equine anti-thymocyte globulin, High-dose methylprednisolone, Methylprednisolone, Placebo for infusions, Placebo for prednisolone, Prednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Conditions
AMR, Antibody-Mediated Rejection, Biopsy-proven Histologic Scores, Kidney Transplantation
Interventions
ALXN2030, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 16 more
Conditions
Chronic Kidney Diseases, End Stage Kidney Disease (ESRD), Major Depressive Disorder
Interventions
Behavioral activation therapy, Bupropion, Clinical Management, Placebo
Behavioral · Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Stony Brook, New York • Dallas, Texas • Seattle, Washington
Conditions
Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
54
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Metformin in Alzheimer's Dementia Prevention

NCT04098666
Conditions
Mild Cognitive Impairment
Interventions
Placebo oral tablet, extended release metformin
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
22
States / cities
Irvine, California • Palo Alto, California • Washington D.C., District of Columbia + 17 more
Conditions
Neoplasms
Interventions
Cyclophosphamide, Fludarabine, Letetresgene autoleucel (lete-cel, GSK3377794)
Drug
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ofatumumab approved dose, Ofatumumab new dose
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 50 more
Conditions
Alcohol Drinking, Alcohol Problem, Posttraumatic Stress Symptom
Interventions
Activity scheduling, Coaching calls, Cognitive restructuring, Non-core intervention components
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Generalized Myasthenia Gravis, Myasthenia Gravis, Myasthenia Gravis, Generalized, gMG
Interventions
Efgartigimod IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Fresno, California • Boca Raton, Florida + 15 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Washington State Driving Intervention Research Study

NCT06146634
Conditions
Driving Behavior
Interventions
Attention Maintenance Training, Hazard Perception Training, Vehicle Maintenance Training
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
15 Years and older
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting Phase 3 Interventional Results available

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

NCT05774756
Conditions
Hypothalamic Obesity
Interventions
Placebo, Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more